Function of PPAR-γ and its ligands in lung cancer

被引:29
作者
Li, MY [1 ]
Lee, TW [1 ]
Yim, APC [1 ]
Chen, GG [1 ]
机构
[1] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China
关键词
PPAR gamma; ligands; lung cancer; growth inhibition;
D O I
10.1080/10408360600552587
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Peroxisome Proliferator-activated receptors gamma (PPAR gamma) is a transcriptional factor belonging to the ligand-activated nuclear receptor superfamily. PPAR gamma is highly expressed in adipose tissue and has a dominant regulatory role in adipocyte differentiation. In humans, PPAR gamma is expressed in multiple tissues such as the breast, colon, lung, ovary, and placenta. In addition to adipogenic and anti-inflammatory effects, PPAR gamma activation has been shown to be anti-proliferative by, virtue of its differentiation-promoting effect, suggesting that activation of PPAR gamma may be useful in slowing or arresting the proliferation of de-differentiated tumor cells. A number of PPAR gamma ligands, such as natural prostaglandins and synthetic anti-diabetic thiazolidinediones (TZDs), have been identified. The discovery of PPAR gamma agonists has enabled the elucidation of the mechanisms involved in the multiple effects of PPAR gamma an the inhibition of tumor cell growth. The importance of this transcription factor in physiology and pathophysiology has stimulated much research in this field. This review describes structural fratures of PPAR gamma, mechanisms of PPAR gamma gene transcription, and recent developments in the discovery of its biological functions on growth inhibition of lung tumors. Prospects for future research leading to new therapies for lung cancer are also discussed.
引用
收藏
页码:183 / 202
页数:20
相关论文
共 99 条
[1]  
Adachi M, 2000, CLIN CANCER RES, V6, P96
[2]   Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site [J].
Adams, M ;
Reginato, MJ ;
Shao, DL ;
Lazar, MA ;
Chatterjee, VK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (08) :5128-5132
[3]   Ligand-independent activation of peroxisome proliferator-activated receptor-γ by insulin and C-peptide in kidney proximal tubular cells -: Dependent on phosphatidylinositol 3-kinase activity [J].
Al-Rasheed, NM ;
Chana, RS ;
Baines, RJ ;
Willars, GB ;
Brunskill, NJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (48) :49747-49754
[4]   Selective activation of PPARγ in breast, colon, and lung cancer cell lines [J].
Allred, CD ;
Kilgore, MW .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2005, 235 (1-2) :21-29
[5]   Inhibition of β-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARγ agonists [J].
Andela, VB ;
Altuwaijri, S ;
Wood, J ;
Rosier, RN .
FEBS LETTERS, 2005, 579 (07) :1765-1769
[6]   Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition [J].
Avis, I ;
Martínez, A ;
Tauler, J ;
Zudaire, E ;
Mayburd, A ;
Abu-Ghazaleh, R ;
Ondrey, F ;
Mulshine, JL .
CANCER RESEARCH, 2005, 65 (10) :4181-4190
[7]   The mechanisms of action of PPARs [J].
Berger, J ;
Moller, DE .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435
[8]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366
[9]   Protein kinase C (PKC) η-mediated PKCμ activation modulates ERK and JNK signal pathways [J].
Brändlin, I ;
Hübner, S ;
Eiseler, T ;
Martinez-Moya, M ;
Horschinek, A ;
Hausser, A ;
Link, G ;
Rupp, S ;
Storz, P ;
Pfizenmaier, K ;
Johannes, FJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (08) :6490-6496
[10]   Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) [J].
Bren-Mattison, Y ;
Van Putten, V ;
Chan, D ;
Winn, R ;
Geraci, MW ;
Nemenoff, RA .
ONCOGENE, 2005, 24 (08) :1412-1422